secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-06-02T11:05:07+00:00
Accession:  0001193125-26-252474
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones
--------------------------------------------------------------------------------

- Exclusive license for civorebrutinib (BTK inhibitor) outside China and select East/Southeast Asia countries.
- Upfront payment of $112.5M; potential milestones up to ~$1.03B across up to five indications.
- Tiered royalties from high single-digit to double-digit percentages on net sales in Territory.
- Travere responsible for development and commercialization in Territory; global trial costs shared with Everest.
- Deal effective upon HSR clearance; Travere can terminate and get upfront refund if tech transfer fails.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/0001193125-26-252474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/d107618d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-252474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer